ArticleJournal of cardiothoracic surgery2025
Multimodality approach for locally advanced lung cancer: when is surgery most beneficial?
Article in Journal of cardiothoracic surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundStage III non-small cell lung cancer (NSCLC) is a complex and challengingdisease due to its variability and the absence of standardized treatment protocols. Thisstudy aimed to investigate the role of surgical resection as part of a multimodal treatmentapproach to improve overall survival (OS) and disease-free survival (DFS) in resource-limited settings.
methodsThe medical records of 309 patients who underwent surgery for confirmed primary lung cancer at the King Hussein Cancer Center (KHCC) in Amman, Jordan, between 2016 and 2022 were reviewed. 59 of them diagnosed with Stage III NSCLC underwent curative surgeries. Patients were grouped into three categories: surgery alone, neoadjuvant therapy followed by surgery, and surgery combined with adjuvant therapy. Demographic, clinical, and survival data were statistically analyzed to compare the outcomes across these groups.
resultsThe study cohort consisted predominantly of males (86.4%), withadenocarcinoma being the most common histological subtype (54.2%). Patients whounderwent surgery alone had the lowest recurrence rate and highest three-year OS andDFS rates (66.7%). Improved OS and DFS were observed in patients with pN0 status andno evidence of lymphovascular invasion (LVI). Minimally invasive surgical approaches suchas VATS were associated with better perioperative outcomes than open surgery.
conclusionSurgical resection, particularly when achieving negative margins (R0) inpatients with N0 disease, is critical for improving survival in patients with Stage IIINSCLC. Multimodal strategies can enhance these benefits further. However, challengesrelated to healthcare access in resource-limited settings highlight the need for customizedtreatment protocols and broader access to advanced medical therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.